ArticleScience advances2021
Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy.
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 66 citations in OpenAlex.
- Molecular-gated MRIMaterials today. Bio · 2026Article
- Multivalent Bi-Specific Nanoerythrosomes: A Two-Birds-One-Stone Approach to Combine Homologous and Active Targeting for Effective Thrombolysis.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Polymersomes preventing brain infiltration of CD177Nature communications · 2026Article
- Harnessing Folate-Mediated PSMA Targeting for Precision Therapy: An Intelligent Liposomal Nanoplatform Against Prostate Cancer.Pharmaceutics · 2026Article
- In situ coagulation environment regulation-assisted thrombus clearance via hydrogenated silicon-based nanothrombolytics.Science advances · 2026Article
- Tumour-resident oncolytic bacteria trigger potent anticancer effects through selective intratumoural thrombosis and necrosis.Nature biomedical engineering · 2026Article
- Cocklebur-inspired magnetic nanomotors for targeted thrombus therapy.Bioactive materials · 2026Article
- Stimuli-Responsive Biomimetic Nanomedicines for Targeted Therapy in Ischemic Stroke: Design Principles, Preclinical Evidence and Translational Challenges.International journal of nanomedicine · 2026Review
- Dual-responsive and NIR-triggered detachable nanoplatform for integrated thrombolytic and antiplatelet therapy.Asian journal of pharmaceutical sciences · 2025Article
- Micrometer-scale tPA beads amplify plasmin generation for enhanced thrombolytic therapy.Bioengineering & translational medicine · 2025Article
- Photothermal-Therapy-Based Targeting Thrombolytic Therapy.ACS applied bio materials · 2025Review
- Artificial biomarker-based feedback-regulated personalized and precise thrombolysis with lower hemorrhagic risk.Science advances · 2025Article
- A Dual-Targeted Therapy with Fucoidan-Functionalized Thrombolytic Discoidal Microparticles for Pulmonary Thromboembolism.Drug design, development and therapy · 2025Article
- Advances in drug delivery systems utilizing blood cells and their membrane-derived microvesicles.Drug delivery · 2024Review
- Tea polyphenol-derived nanomedicine for targeted photothermal thrombolysis and inflammation suppression.Journal of nanobiotechnology · 2024Article
- pH-Responsive Theranostic Colloidosome Drug Carriers Enable Real-Time Imaging of Targeted Thrombolytic Process with Near-Infrared-II for Deep Venous Thrombosis.Research (Washington, D.C.) · 2024Article
- Redox-responsive peptide-based complex coacervates as delivery vehicles with controlled release of proteinous drugs.Communications chemistry · 2023Article
- Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy.Journal of thrombosis and haemostasis : JTH · 2023Article
- Recent Advances in Blood Cell-Inspired and Clot Targeted Thrombolytic Therapies.Journal of tissue engineering and regenerative medicine · 2023Review
- Puffball-Inspired Microrobotic Systems with Robust Payload, Strong Protection, and Targeted Locomotion for On-Demand Drug Delivery.Advanced materials (Deerfield Beach, Fla.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to activated platelets, we report a fibrinogen-mimicking, multiarm nanovesicle for thrombus-specific tPA delivery and targeted thrombolysis. This biomimetic system is based on the lipid nanovesicle coated with polyethylene glycol (PEG) terminally conjugated with a cyclic RGD (cRGD) peptide. Our experiments with human blood demonstrated its highly selective binding to activated platelets and efficient tPA release at a thrombus site under both static and physiological flow conditions. Its clot dissolution time in a microfluidic system was comparable to that of free tPA. Furthermore, we report a purpose-built computational model capable of simulating targeted thrombolysis of the tPA-loaded nanovesicle and with a potential in predicting the dynamics of thrombolysis in physiologically realistic scenarios. This combined experimental and computational work presents a promising platform for development of thrombolytic nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.